Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.

Tecan Journal dot

Selected category: Resolvex A200

Back to overview

Interfering with heart disease

Developing drugs that are effective, with minimal side effects, is important to improve the lives of patients suffering from serious diseases. Leading biotechnology company Amgen focuses on producing therapies for a wide range of conditions, and is currently developing small interfering RNAs (siRNAs) as a method to treat patients with a genetic predisposition to heart disease.

Read more
empty cart | close cart
Your cart

Your cart is empty.

Get a quote close form